Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices

被引:64
|
作者
Sarfati, Diana [1 ]
Gurney, Jason [1 ]
Stanley, James [1 ]
Salmond, Clare
Crampton, Peter [2 ]
Dennett, Elizabeth [3 ]
Koea, Jonathan [4 ]
Pearce, Neil [5 ,6 ]
机构
[1] Univ Otago, Sch Med & Hlth Sci, Dept Publ Hlth, Wellington 6022, New Zealand
[2] Univ Otago, Fac Hlth Sci, Dunedin 9054, New Zealand
[3] Univ Otago, Sch Med & Hlth Sci, Dept Surg & Anaesthesia, Wellington 6022, New Zealand
[4] North Shore Hosp, Dept Surg, Waitemata Dist Hlth Board, Auckland 0740, New Zealand
[5] Massey Univ, Ctr Publ Hlth Res, Wellington 6022, New Zealand
[6] Univ London London Sch Hyg & Trop Med, Dept Med Stat, London WC1E 7HT, England
关键词
Comorbidity; Multimorbidity; Cancer; Measurement; Validity; Indices; BREAST-CANCER; PROSTATE-CANCER; MEDICAL-RECORD; CO-MORBIDITY; METFORMIN; SURVIVAL; ICD-9-CM; ILLNESS; IMPACT; RISK;
D O I
10.1016/j.jclinepi.2013.11.012
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: We aimed to develop and validate administrative data based comorbidity indices for a range of cancer types that included all relevant concomitant conditions. Study Design and Settings: Patients diagnosed with colorectal, breast, gynecological, upper gastrointestinal, or urological cancers identified from the National Cancer Registry between July 1, 2006 and June 30, 2008 for the development cohort (n = 14,096) and July 1, 2008 to December 31, 2009 for the validation cohort (n = 11,014) were identified. A total of 50 conditions were identified using hospital discharge data before cancer diagnosis. Five site-specific indices and a combined site index were developed, with conditions weighted according to their log hazard ratios from age- and stage-adjusted Cox regression models with noncancer death as the outcome. We compared the performance of these indices (the C3 indices) with the Charlson and National Cancer Institute (NCI) comorbidity indices. Results: The correlation between the Charlson and C3 index scores ranged between 0.61 and 0.78. The C3 index outperformed the Charlson and NCI indices for all sites combined, colorectal, and upper gastrointestinal cancer, performing similarly for urological, breast, and gynecological cancers. Conclusion: The C3 indices provide a valid alternative to measuring comorbidity in cancer populations, in some cases providing a modest improvement over other indices. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:586 / 595
页数:10
相关论文
共 32 条
  • [31] Adjuvant chemotherapy does not improve cancer-specific survival for pathologic stage II/III rectal adenocarcinoma after neoadjuvant chemoradiotherapy and surgery: evidence based on long-term survival analysis from SEER data
    Liao, Hualin
    Zeng, Tengyu
    Xie, Xianqiang
    Li, Jiyang
    Li, Dongsheng
    Chen, Fan
    Zhu, Hongliang
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2023, 38 (01)
  • [32] Adjuvant chemotherapy does not improve cancer-specific survival for pathologic stage II/III rectal adenocarcinoma after neoadjuvant chemoradiotherapy and surgery: evidence based on long-term survival analysis from SEER data
    Hualin Liao
    Tengyu Zeng
    Xianqiang Xie
    Jiyang Li
    Dongsheng Li
    Fan KejinYan
    Hongliang Chen
    International Journal of Colorectal Disease, 38